リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Temporal Trend in an Initial Treatment, Survival, and Medical Costs Among Patients With Lung Cancer Between 2013 and 2018 in Kyoto City, Japan」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Temporal Trend in an Initial Treatment, Survival, and Medical Costs Among Patients With Lung Cancer Between 2013 and 2018 in Kyoto City, Japan

Shimamoto, Tomonari Tateyama, Yukiko Kobayashi, Daisuke Yamamoto, Keiichi Takahashi, Yoshimitsu Ueshima, Hiroaki Sasaki, Kosuke Nakayama, Takeo Iwami, Taku 京都大学 DOI:10.1016/j.vhri.2022.05.004

2022.09

概要

OBJECTIVES: This study aimed to identify the variation of treatment contents and outcomes and economic burden of lung cancer among the elderly population in Japan. METHODS: New-onset primary lung cancer from April 2013 to March 2019 were identified by using the Kyoto City administrative database for National Health Insurance and Advanced Elderly Medical Service System. Patient characteristics, initial treatment, medical costs, and deaths were analyzed. Continuous variables were calculated using standard descriptive statistical methods. RESULTS: A total of 4845 people who were diagnosed as having lung cancer and received any treatment between 2013 and 2018 were included in the study. The average age of patients was 73 to 74 years for a 6-year study period. The proportion of patients who received surgery, drug therapy, and radiation therapy as initial treatment was 31% to 42%, 36% to 44%, and 21% to 24%, respectively. Healthcare costs increased between fiscal year (FY) 2014 and FY 2018, with a particularly significant increase of 340 million for drug therapy, whereas the mortality rate in <2-year follow-up decreased from 42.7% in FY 2013 to 368% in FY 2016. CONCLUSIONS: This cross-sectional study demonstrated that the improvement in the survival rate and proportion of surgery as an initial treatment was increased whereas drug therapy decreased and medical costs increased among patients with lung cancer over time. Based on these results, it is necessary to implement sustainable healthcare measures with a consideration of cost-effectiveness.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Global Cancer Observatory: cancer today. International Agency for Research on Cancer, World Health Organization. https://gco.iarc.fr/today. Accessed October 30, 2021.

2. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: cancer today. Japan Factsheet. International Agency for Research on Cancer. https://gco.iarc.fr/today/ data/factsheets/populations/392/japan/fact/sheets.pdf. Accessed November 16, 2021.

3. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR- mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2): 113–125.

4. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non- small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.

5. General condition of national medical expenditure. Ministry of Health, La- bour and Welfare. https://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/18/dl/ kekka.pdfJapanese. Accessed October 30, 2021.

6. Population of the elderly (Japanese). Statistics Bureau, Ministry of Internal Affairs and Communications. http://www.stat.go.jp/data/topics/topi1291. html. Accessed March 31, 2022.

7. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(7): 593–602.

8. Incisive Health. Cancer Research UK. https://www.cancerresearchuk.org/ sites/default/files/saving_lives_averting_costs.pdf. Accessed October 30, 2021.

9. Cressman S, Lam S, Tammemagi MC, et al. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol. 2014;9(10):1449–1458.

10. Bravo-Iñiguez C, Perez Martinez M, Armstrong KW, Jaklitsch MT. Surgical resection of lung cancer in the elderly. Thorac Surg Clin. 2014;24(4):371–381.

11. Ikegami N, Yoo BK, Hashimoto H, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2011;378(9796): 1106–1115.

12. Japan: Kyoto City. Kyoto city statistics portal. https://www2.city.kyoto.lg.jp/ sogo/toukei/Population/Suikei/Japanese. Accessed October 30, 2021.

13. Survey on national health insurance. Statistics Bureau of Japan. https://www. e-stat.go.jp/stat-search/files?page=1&toukei=00450397. Accessed October 30, 2021.

14. Survey on advanced elderly medical service system. Statistics Bureau of Japan. https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450388 &tstat=000001044907. Accessed October 30, 2021.

15. Basic resident register population (Japanese). Japan. Kyoto City. https://www.city. kyoto.lg.jp/hokenfukushi/cmsfiles/contents/0000210/210037/29unneikeikaku. pdf. Accessed October 30, 2021.

16. Gon Y, Kabata D, Yamamoto K, et al. Validation of an algorithm that de- termines stroke diagnostic code accuracy in a Japanese hospital-based cancer registry using electronic medical records. BMC Med Inform Decis Mak. 2017;17(1):157.

17. Gon Y, Yamamoto K, Mochizuki H. The accuracy of diagnostic codes in electronic medical records in Japan. J Med Syst. 2019;43(10):315.

18. Iwagami M, Aoki K, Akazawa M, et al. Task force report on the validation of diagnosis codes and other outcome definitions in the Japanese receipt data. Jpn J Pharmacoepidemiol. 2018;23(2):95–123.

19. Tsutui T, Muramatsu N. Care-needs certification in the long-term care in- surance system of Japan. J Am Geriatr Soc. 2005;53(3):522–527.

20. Guidelines for diagnosis and treatment of the lung cancer 2013-2018 (Japa- nese). The Japan Lung Cancer Society. https://www.haigan.gr.jp/modules/ guideline/index.php?content_id=20. Accessed October 30, 2021.

21. van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer. Lancet. 2011;378(9804):1741–1755.

22. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Pre- vention. Clin Chest Med. 2020;41(1):1–24.

23. Cheng TYD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The in- ternational epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11(10):1653–1671.

24. National health and nutrition survey 2019. Ministry of Health, Labour and Welfare. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/ kenkou/eiyou/r1-houkoku_00002.html. Accessed October 30, 2021.

25. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019 22;85(1):8.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る